Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 20/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 12/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14267711 | 0.92 | ADORA2B (1.00) | ADORA2BADORA1 | |
| SCHEMBL14267755 | 0.91 | ADORA2B (0.84) | ADORA2BADORA1 | |
| SCHEMBL14267689 | 0.91 | ADORA2B (1.00) | ADORA2BADORA1 | |
| SCHEMBL14267688 | 0.90 | ADORA2B (1.00) | ADORA2BADORA1 | |
| SCHEMBL4759504 | 0.90 | ADORA2B (0.81) | ADORA2BADORA1 | |
| SCHEMBL14267732 | 0.89 | ADORA2B (0.85) | ADORA2BADORA1 | |
| SCHEMBL14267726 | 0.89 | ADORA2B (1.00) | ADORA2BADORA1 | |
| SCHEMBL1778224 | 0.89 | ADORA2B (0.80) | ADORA2BADORA1 | |
| SCHEMBL14293822 | 0.89 | ADORA2B (1.00) | ADORA2BADORA1 | |
| SCHEMBL14267682 | 0.88 | ADORA2B (1.00) | ADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 294 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025213239-A1 | OPERATIONAL METHOD FOR MANAGING REVERSE LOGISTICS OF ELECTRICAL AND ELECTRONIC WASTE | DEVOLVA GESTÃO INTEGRADA DE LOGÍSTICA REVERSA LTDA (BR) | 2025-10-16 | — | — | WO | claimed |
| EP-4567112-A1 | RNA INHIBITOR FOR INHIBITING APOC3 GENE EXPRESSION AND USE THEREOF | Kylonova (Xiamen) Biopharma Co., Ltd. (CN) | 2025-06-11 | — | — | EP | claimed |
| US-20250177423-A1 | PHOTORESPONSIVE PEPTIDE DELIVERY SYSTEM AND METHOD OF USING THE SAME | THE UNIVERSITY OF HONG KONG (CN) | 2025-06-05 | — | — | US | claimed |
| CN-119643735-A | Method for determining human angiotensin II purity standard substance | 广东省计量科学研究院（华南国家计量测试中心） | 2025-03-18 | — | — | CN | claimed |
| CN-118799162-A | Watermark embedding and extracting method for human motion capture data | 杭州电子科技大学 | 2024-10-18 | — | — | CN | claimed |
| US-20240251664-A1 | LIGHT EMITTING ELEMENT AND AMINE COMPOUND FOR THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2024-07-25 | — | — | US | claimed |
| CN-118325784-A | Arthrobacter nitroguaiacum AS16 and application thereof | 江苏省农业科学院 | 2024-07-12 | — | — | CN | claimed |
| CN-114577936-B | Separation detection method of beta-nicotinamide mononucleotide in capsule | 中科谱研（北京）科技有限公司 | 2024-06-04 | — | — | CN | claimed |
| CN-117665193-A | Method for detecting phytic acid by utilizing ion chromatography | 内蒙古伊利实业集团股份有限公司 | 2024-03-08 | — | — | CN | claimed |
| CN-116829677-A | Conversion of biomass to LPG | 阿邦迪亚生物质液化有限公司 | 2023-09-29 | — | — | CN | claimed |
| EP-4188594-A1 | MOF-BASED PRODUCT AND METHOD FOR PRODUCING MOF-BASED PRODUCTS | SAINT-GOBAIN CENTRE DE RECHERCHES ET D'ETUDES EUROPEEN (FR) | 2023-06-07 | — | — | EP | claimed |
| CN-112581461-B | No-reference image quality evaluation method and device based on generation network | 深圳大学 | 2023-06-02 | — | — | CN | claimed |
| WO-2022269184-A1 | PROCESS FOR PRODUCING A MOF-BASED PRODUCT AND POWDER OF GRAINS COMPOSED OF A MOF-BASED PRODUCT | SAINT-GOBAIN CENTRE DE RECHERCHE ET D'ETUDES EUROPEEN (FR) | 2022-12-29 | — | — | WO | claimed |
| CN-114954454-A | Cruise control method and device for automatic driving low-speed following vehicle | 岚图汽车科技有限公司 | 2022-08-30 | — | — | CN | claimed |
| CN-112904658-B | Lens assembly, illumination module and projection equipment | 江西欧迈斯微电子有限公司 | 2022-04-12 | — | — | CN | claimed |
| CN-114276291-A | Process for preparing malononitrile oxime ether compounds and intermediate compounds | 沈阳中化农药化工研发有限公司 | 2022-04-05 | — | — | CN | claimed |
| WO-2022023660-A1 | MOF-BASED PRODUCT AND METHOD FOR PRODUCING MOF-BASED PRODUCTS | SAINT-GOBAIN CENTRE DE RECHERCHES ET D'ETUDES EUROPEEN (FR) | 2022-02-03 | — | — | WO | claimed |
| EP-2694074-A1 | USE OF A2B ADENOSINE RECEPTOR ANTAGONISTS FOR TREATING HEART FAILURE AND ARRHYTHMIA IN POST-MYOCARDIAL INFARCTION PATIENTS | Gilead Sciences, Inc. (US) | 2014-02-12 | — | — | EP | claimed |
| WO-2012154340-A1 | USE OF A2B ADENOSINE RECEPTOR ANTAGONISTS FOR TREATING HEART FAILURE AND ARRHYTHMIA IN POST-MYOCARDIAL INFARCTION PATIENTS | GILEAD SCIENCES, INC. (US) | 2012-11-15 | — | — | WO | claimed |
| US-20120258974-A1 | USE OF A2B ADENOSINE RECEPTOR ANTAGONISTS FOR TREATING HEART FAILURE AND ARRHYTHMIA IN POST-MYOCARDIAL INFARCTION PATIENTS | GILEAD SCIENCES, INC. | 2012-10-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258974-A1 | USE OF A2B ADENOSINE RECEPTOR ANTAGONISTS FOR TREATING HEART FAILURE AND ARRHYTHMIA IN POST-MYOCARDIAL INFARCTION PATIENTS | ADORA2B, ADORA2A, ADRA2B | ADORA2B 1/4885ADORA1 5/4885 |
| US-20250177423-A1 | PHOTORESPONSIVE PEPTIDE DELIVERY SYSTEM AND METHOD OF USING THE SAME | DNPEP, LNPEP, VIP | ADORA2B 4198/4885ADORA1 2833/4885 |
| US-20240251664-A1 | LIGHT EMITTING ELEMENT AND AMINE COMPOUND FOR THE SAME | NES, NFE2L2, NUCB2 | ADORA2B 1076/4885ADORA1 1078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.